Diversity, Equity, and Inclusion Champion

Hideho Okada, MD, PhD

Title(s)Professor, Neurological Surgery
SchoolSchool of Medicine
Address1450 Third Street, #472
San Francisco CA 94158
Phone415-476-1637
PronounsHe/Him/His
ORCID ORCID Icon0000-0003-0076-9920 Additional info
vCardDownload vCard

Collapse Biography 
Collapse education and training
Nagoya University M.D.1991School of Medicine
Nagoya University Ph.D.1996School of Medicine
Nagoya University Graduate School of Medicine, Nagoya, Japan08/2003Residency of Neurosurgery
University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training
Collapse awards and honors
Pacific Pediatric Neuro-Oncology Consortium (PNOC)2023  - 2023Basic Research Trailblazer Award
Alliance For Cancer Gene Therapy2022  - 2022Investigator Award
Society for Neuro-Oncology2022  - 2022Keynote Lecturer at the 2022 Annual Meeting of Society for Neuro-Oncology
The Labatt Brain Tumour Research Centre at the University of Toronto2021  - 2021Mike and Dianne Traynor Lectureship
American Association for Cancer Research2018  - 2018Chair: AACR Special Conference, Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy. February 12 - 15, 2018. San Diego
Show more

Collapse Overview 
Collapse overview
Dr. Okada is a creative physician-scientist who has developed therapeutic modalities in the laboratory, translated them into clinical protocols, and used his expertise as both scientist and clinician to assess the clinical data from ongoing trials. Dr. Okada's work has consistently focused on immunotherapeutic strategies aimed at a daunting challenge in oncology – malignant brain tumors. Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. Dr. Okada's success in navigating the detailed regulatory processes required for such trials demonstrates his attention to detail and breadth of knowledge, spanning from basic science to clinical care. Dr. Okada's lab work was the first to identify and fully characterize cytotoxic T-lymphocyte (CTL) epitopes for gliomas. Dr. Okada's seminal discovery of CTL epitopes in glioma-associated antigens and the work on the mechanisms underlying the adjuvant effects of poly-ICLC enabled him to launch novel glioma vaccine trials in combination with poly-ICLC as an adjuvant. These efforts have also been supported by his mechanistic studies delineating the role of an integrin receptor very late activation antigen (VLA)-4 and chemokine CXCL10 in the efficient trafficking of T-cells to brain tumor sites. Dr. Okada has held 10 Investigational New Drug approvals that the FDA approved for early-phase clinical trials, including genetically engineered glioma vaccines and T cell receptor (TCR)- or chimeric antigen receptor (CAR)-transduced T cell therapy in both adult and pediatric patients. For example, Dr. Okada has developed a chimeric antigen receptor (CAR) against epidermal growth factor receptor (EGFR)vIII, which has been evaluated in patients with EGFRvIII+ GBM. Recently, Dr. Okada developed a novel synNotch-primed CAR system with Dr. Wendell Lim to overcome the antigen-heterogeneity, off-tumor toxicity, and T-cell exhaustion issues. Dr. Okada’s team has also pioneered discoveries of novel immunoregulatory mechanisms in gliomas, such as one mediated by myeloid-derived suppressor cells (MDSC) and mutations of the isocitrate dehydrogenase (IDH)1 and IDH2. As a thought leader, to improve radiologic evaluation criteria for patients undergoing immunotherapy, Dr. Okada led an international group of brain tumor immunotherapy experts to develop novel Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria. Dr. Okada is an elected member of the American Society for Clinical Investigation (2010-present), an honored society for physicians who promote laboratory science to the clinic. Dr. Okada also serves as an Associate Editor for Neuro-Oncology, the most prominent journal for brain tumor research.
Show more

Collapse Research 
Collapse research activities and funding
CALIF Inst for Regenerative Medicine
CLIN2-15562Apr 1, 2024 - Mar 31, 2028
Role: PI
Description: Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma $ 7,800,000. total To conduct the Phase 1 study of autologous E-SYNC T cell therapy in adult participants with EGFRvIII+ glioblastoma.
Brain SPORE
NIH/NCI CA097257Sep 1, 2023 - Aug 31, 2028
Role: Basic Science Director, Co-Director of the Administrative Core and Co-Leader of Project 3
Description: This SPORE project represents the efforts of interdisciplinary teams of investigators from the Neuro-Oncology Program to build on our accomplishments to continue to translate our findings to improve care for patients with brain cancer. We have three specific objectives: (1) to develop novel peripheral blood-based biomarkers for glioma patients, (2) to identify novel metabolic markers for noninvasive imaging to evaluate tumor burden and treatment response, and (3) to develop a novel immunotherapy strategy to overcome the current significant challenges. I am the Basic Science Director of the entire SPORE project. I also serve as a Co-Director of the Administrative Core and Co-Leader of Project 3. The goal of Project 3 is to develop and conduct a phase I study of B-SYNC T cell therapy to determine its safety and biological activities in patients with glioblastoma.
Advancing treatment and understanding of immunotherapy in glioblastoma (NCI U19 Glioblastoma Therapeutics Network).
NIH/NCI 1 U19 CA264338-01Sep 1, 2021 - Aug 31, 2026
Role: The project leader of Project 2
Description: There are two research projects and two cores. Dr. Okada is a co-leader of Project 2 along with Dr. Jennifer Clarke. The goal of Project 2 is to develop the novel synNotch CART cell therapy through IND-enabling studies, IND submission, and conduct a phase I trial in adult patients with recurrent EGFRvIII+ glioblastoma.
Advancing treatment and understanding of immunotherapy in glioblastoma (NCI U19 Glioblastoma Therapeutics Network).
NIH/NCI 1 U19 CA264338-01Sep 1, 2021 - Aug 31, 2026
Role: The project leader of Project 2
Description: There are two research projects and two cores. Dr. Okada is a co-leader of Project 2 along with Dr. Jennifer Clarke. The goal of Project 2 is to develop the novel synNotch CART cell therapy through IND-enabling studies, IND submission, and conduct a phase I trial in adult patients with recurrent EGFRvIII+ glioblastoma.
Preclinical development of breakthrough immunotherapy for brain tumors
NIH R35NS105068Dec 15, 2017 - Nov 30, 2025
Role: Principal Investigator

Collapse ORNG Applications 
Collapse Clinical Trials

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Glioma-neuronal circuit remodeling induces regional immunosuppression. Nat Commun. 2025 May 22; 16(1):4770. Nejo T, Krishna S, Yamamichi A, Lakshmanachetty S, Jimenez C, Lee KY, Baker DL, Young JS, Chen T, Phyu SSS, Phung L, Gallus M, Maldonado GC, Okada K, Ogino H, Watchmaker PB, Diebold D, Choudhury A, Daniel AGS, Cadwell CR, Raleigh DR, Hervey-Jumper SL, Okada H. PMID: 40404658; PMCID: PMC12098748.
    View in: PubMed   Mentions:    Fields:    
  2. FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma. Nat Commun. 2025 May 22; 16(1):4751. Beffinger M, Schellhammer L, Taskoparan B, Deplazes S, Salazar U, Tatari N, Seehusen F, von Balthazar L, Zinner CP, Spath S, Shekarian T, Ritz MF, McDaid M, Egloff P, Zimmermann I, Okada H, Ward ES, Rohrer J, Seeger MA, Buch T, Hutter G, Vom Berg J. PMID: 40404625; PMCID: PMC12098678.
    View in: PubMed   Mentions:    Fields:    
  3. Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad Scope and Implementation - A Progress Report. Neuro Oncol. 2025 May 03. van den Bent MJ, Vogelbaum MA, Cloughesy T, Galldiks N, Albert NL, Tonn JC, Avila E, Fangusaro J, Mirsky D, Sahgal A, Soffietti R, Karschnia P, Mehta M, Kim MM, Boele F, Huse JT, Nayak L, Lim-Fat MJ, le Rhun E, Desjardins A, Lee EQ, Chukwueke U, Koekkoek JAF, Mendoza T, Loughan AR, Budhu JA, Bakas S, Huang RY, Villanueva-Meyer JE, Leone JP, Okada H, Reardon DA, Bi WL, Wen PY, Chang SM. PMID: 40317212.
    View in: PubMed   Mentions:    Fields:    
  4. The TCR Repertoire: A Window Into Pediatric Brain Tumor Immunity. Neuro Oncol. 2025 Apr 30. Nejo T, Prins RM, Okada H. PMID: 40305478.
    View in: PubMed   Mentions:    Fields:    
  5. Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model. Neurooncol Adv. 2025 Jan-Dec; 7(1):vdaf074. Hatae R, Watchmaker PB, Yamamichi A, Kyewalabye K, Okada K, Phyu S, Goretsky Y, Haegelin J, Pineo-Cavanaugh P, Gallus M, Phung L, Chen T, Long H, Chuntova P, Raulet DH, Terabe M, Okada H. PMID: 40376677; PMCID: PMC12080550.
    View in: PubMed   Mentions:
  6. Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence. bioRxiv. 2025 Apr 09. Piyadasa H, Oberlton B, Ribi M, Ranek JS, Averbukh I, Leow K, Amouzgar M, Liu CC, Greenwald NF, McCaffrey EF, Kumar R, Ferrian S, Tsai AG, Filiz F, Fullaway CC, Bosse M, Varra SR, Kong A, Sowers C, Gephart MH, Nuñez-Perez P, Yang E, Travers M, Schachter MJ, Liang S, Santi MR, Bucktrout S, Gherardini PF, Connolly J, Cole K, Barish ME, Brown CE, Oldridge DA, Drake RR, Phillips JJ, Okada H, Prins R, Bendall SC, Angelo M. PMID: 40161803; PMCID: PMC11952471.
    View in: PubMed   Mentions:
  7. Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nature. 2025 Mar; 639(8054):463-473. Kwok DW, Stevers NO, Etxeberria I, Nejo T, Colton Cove M, Chen LH, Jung J, Okada K, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Liu J, Wu SH, Ramos E, Yamamichi A, Watchmaker PB, Ogino H, Saijo A, Du A, Grishanina NR, Woo J, Diaz A, Hervey-Jumper SL, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA, Costello JF, Okada H. PMID: 39972144; PMCID: PMC11903331.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
  8. Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations. Neuro Oncol. 2025 Feb 10; 27(2):352-368. Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J, Okada H. PMID: 39450490; PMCID: PMC11812040.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
  9. Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review. JAMA Neurol. 2025 Jan 01; 82(1):93-103. Ismail FS, Gallus M, Meuth SG, Okada H, Hartung HP, Melzer N. PMID: 39585688.
    View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
  10. Programming tissue-sensing T cells that deliver therapies to the brain. Science. 2024 Dec 06; 386(6726):eadl4237. Simic MS, Watchmaker PB, Gupta S, Wang Y, Sagan SA, Duecker J, Shepherd C, Diebold D, Pineo-Cavanaugh P, Haegelin J, Zhu R, Ng B, Yu W, Tonai Y, Cardarelli L, Reddy NR, Sidhu SS, Troyanskaya O, Hauser SL, Wilson MR, Zamvil SS, Okada H, Lim WA. PMID: 39636984; PMCID: PMC11900893.
    View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
  11. Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma. Neuro Oncol. 2024 Dec 05; 26(12):2272-2287. Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H. PMID: 39115195; PMCID: PMC11630541.
    View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
  12. IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1850-1866. Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, Guemes M, Galic Z, Phyu S, Okada H, Grausam KB, Breunig JJ, Brown CE, Nathanson DA, Prins RM, Chen YY. PMID: 38982561; PMCID: PMC11449012.
    View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
  13. Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System. J Vis Exp. 2024 Sep 13; (211). Kim K, Gallus M, Xiao T, Parchure AS, Shah BR, Okada H, Diederich C, Ozhinsky E, Narsinh K. PMID: 39345114.
    View in: PubMed   Mentions: 1     Fields:    Translation:Animals
  14. Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier. Nat Commun. 2024 Sep 13; 15(1):8021. Guo Y, Lee H, Kim C, Park C, Yamamichi A, Chuntova P, Gallus M, Bernabeu MO, Okada H, Jo H, Arvanitis C. PMID: 39271721; PMCID: PMC11399249.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
  15. Activating the dark genome to illuminate cancer vaccine targets. Nat Genet. 2024 Sep; 56(9):1770-1771. Kwok DW, Okada H, Costello JF. PMID: 39223317; PMCID: PMC11456370.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  16. Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas? Vaccines (Basel). 2024 Aug 01; 12(8). Phung LH, Nejo T, Okada H. PMID: 39203988; PMCID: PMC11359082.
    View in: PubMed   Mentions:
  17. Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era. J Clin Oncol. 2024 Jul 20; 42(21):2588-2598. Kotecha R, Schiff D, Chakravarti A, Fleming JL, Brown PD, Puduvalli VK, Vogelbaum MA, Gondi V, Gallus M, Okada H, Mehta MP. PMID: 38833641; PMCID: PMC11283772.
    View in: PubMed   Mentions: 2     Fields:    Translation:Humans
  18. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives. Cells. 2024 04 23; 13(9). Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H. PMID: 38727262; PMCID: PMC11083543.
    View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
  19. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment. JCI Insight. 2024 Apr 08; 9(7). Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H. PMID: 38386420; PMCID: PMC11128202.
    View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
  20. IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma. bioRxiv. 2024 Apr 03. Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H. PMID: 38617245; PMCID: PMC11014587.
    View in: PubMed   Mentions:
  21. Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma. Sci Rep. 2024 03 16; 14(1):6362. Nejo T, Wang L, Leung KK, Wang A, Lakshmanachetty S, Gallus M, Kwok DW, Hong C, Chen LH, Carrera DA, Zhang MY, Stevers NO, Maldonado GC, Yamamichi A, Watchmaker PB, Naik A, Shai A, Phillips JJ, Chang SM, Wiita AP, Wells JA, Costello JF, Diaz AA, Okada H. PMID: 38493204; PMCID: PMC10944514.
    View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
  22. Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest. 2024 Mar 01; 134(5). Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY. PMID: 38426505; PMCID: PMC10904050.
    View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
  23. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol. 2024 02 02; 26(2):335-347. Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H. PMID: 37758193; PMCID: PMC10836773.
    View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
  24. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell. 2024 01 18; 187(2):446-463.e16. Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, Grishanina NR, Kwok D, Stevers NO, Jin Q, Youngblood MW, Stasiak LA, Hou Y, Wang J, Yamaguchi TN, Lafontaine M, Shai A, Smirnov IV, Solomon DA, Chang SM, Hervey-Jumper SL, Berger MS, Lupo JM, Okada H, Phillips JJ, Boutros PC, Gallo M, Oldham MC, Yue F, Costello JF. PMID: 38242087; PMCID: PMC10832360.
    View in: PubMed   Mentions: 48     Fields:    Translation:Humans
  25. Glioblastoma vaccines: past, present, and opportunities. EBioMedicine. 2024 Feb; 100:104963. Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G. PMID: 38183840; PMCID: PMC10808938.
    View in: PubMed   Mentions: 17     Fields:    Translation:Humans
  26. Correction: Gallus et al. Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma. Cancers 2023, 15, 3726. Cancers (Basel). 2023 Dec 26; 16(1). Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H. PMID: 38201665; PMCID: PMC10778241.
    View in: PubMed   Mentions:
  27. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. 2024 01 08; 42(1):1-5. Koschmann C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O, Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, Filbin M, Franson A, Galban S, Garcia Moure M, Garton H, Gowda P, Marques JG, Hawkins C, Heath A, Hulleman E, Ji S, Jones C, Kilburn L, Kline C, Koldobskiy MA, Lim D, Lowenstein PR, Lu QR, Lum J, Mack S, Magge S, Marini B, Martin D, Marupudi N, Messinger D, Mody R, Morgan M, Mota M, Muraszko K, Mueller S, Natarajan SK, Nazarian J, Niculcea M, Nuechterlein N, Okada H, Opipari V, Pai MP, Pal S, Peterson E, Phoenix T, Prensner JR, Pun M, Raju GP, Reitman ZJ, Resnick A, Rogawski D, Saratsis A, Sbergio SG, Souweidane M, Stafford JM, Tzaridis T, Venkataraman S, Vittorio O, Wadden J, Wahl D, Wechsler-Reya RJ, Yadav VN, Zhang X, Zhang Q, Venneti S. PMID: 38039965; PMCID: PMC11067690.
    View in: PubMed   Mentions: 5     Fields:    Translation:Humans
  28. Enhancing CAR-T Cell Metabolism to Overcome Hypoxic Conditions in the Brain Tumor Microenvironment. bioRxiv. 2023 Nov 15. Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H. PMID: 38014236; PMCID: PMC10680638.
    View in: PubMed   Mentions:
  29. Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma. bioRxiv. 2023 Nov 02. Nejo T, Wang L, Leung KK, Wang A, Lakshmanachetty S, Gallus M, Kwok DW, Hong C, Chen LH, Carrera DA, Zhang MY, Stevers NO, Maldonado GC, Yamamichi A, Watchmaker P, Naik A, Shai A, Phillips JJ, Chang SM, Wiita AP, Wells JA, Costello JF, Diaz AA, Okada H. PMID: 37961484; PMCID: PMC10634890.
    View in: PubMed   Mentions: 2  
  30. Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens. bioRxiv. 2023 Oct 20. Kwok DW, Stevers NO, Nejo T, Chen LH, Etxeberria I, Jung J, Okada K, Cove MC, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Wu SH, Ramos E, Yamamichi A, Liu J, Watchmaker P, Ogino H, Saijo A, Du A, Grishanina N, Woo J, Diaz A, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA, Costello JF, Okada H. PMID: 37904942; PMCID: PMC10614978.
    View in: PubMed   Mentions:
  31. Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad115. Gibson D, Ravi A, Rodriguez E, Chang S, Oberheim Bush N, Taylor J, Clarke J, Solomon D, Scheffler A, Witte J, Lambing H, Okada H, Berger M, Chehab F, Butowski NA. PMID: 37899778; PMCID: PMC10611422.
    View in: PubMed   Mentions: 3  
  32. Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma. Cancer Discov. 2023 09 06; 13(9):2090-2105. Lee J, Nicosia M, Hong ES, Silver DJ, Li C, Bayik D, Watson DC, Lauko A, Kay KE, Wang SZ, Johnson S, McGraw M, Grabowski MM, Kish DD, Desai AB, Goodman WA, Cameron SJ, Okada H, Valujskikh A, Fairchild RL, Ahluwalia MS, Lathia JD. PMID: 37378557; PMCID: PMC10481130.
    View in: PubMed   Mentions: 40     Fields:    Translation:AnimalsCells
  33. Glioma-neuronal circuit remodeling induces regional immunosuppression. bioRxiv. 2023 Aug 06. Nejo T, Krishna S, Jimenez C, Yamamichi A, Young JS, Lakshmanachetty S, Chen T, Phyu SSS, Ogino H, Watchmaker P, Diebold D, Choudhury A, Daniel AGS, Raleigh DR, Hervey-Jumper SL, Okada H. PMID: 37577659; PMCID: PMC10418167.
    View in: PubMed   Mentions:
  34. Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma. Cancers (Basel). 2023 Jul 22; 15(14). Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H. PMID: 37509387; PMCID: PMC10378701.
    View in: PubMed   Mentions: 7  
  35. Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell-mediated limbic encephalitis. Sci Adv. 2023 06 09; 9(23):eabq7595. Gallus M, Roll W, Dik A, Barca C, Zinnhardt B, Hicking G, Mueller C, Naik VN, Anstötz M, Krämer J, Rolfes L, Wachsmuth L, Pitsch J, van Loo KMJ, Räuber S, Okada H, Wimberley C, Strippel C, Golombeck KS, Johnen A, Kovac S, Groß CC, Backhaus P, Seifert R, Lewerenz J, Surges R, Elger CE, Wiendl H, Ruck T, Becker AJ, Faber C, Jacobs AH, Bauer J, Meuth SG, Schäfers M, Melzer N. PMID: 37294768; PMCID: PMC10256169.
    View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
  36. Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al. J Immunother Cancer. 2023 03; 11(3). Chheda ZS, Mueller S, Hegde B, Yamamichi A, Butterfield LH, Okada H. PMID: 36944450; PMCID: PMC10032395.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  37. Magnetic Resonance Spectroscopy Metabolites as Biomarkers of Disease Status in Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Treated with Glioma-Associated Antigen Peptide Vaccines. Cancers (Basel). 2022 Dec 05; 14(23). Panigrahy A, Jakacki RI, Pollack IF, Ceschin R, Okada H, Nelson MD, Kohanbash G, Dhall G, Bluml S. PMID: 36497477; PMCID: PMC9739009.
    View in: PubMed   Mentions: 3  
  38. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022 09; 609(7925):174-182. Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. PMID: 36002574; PMCID: PMC9433322.
    View in: PubMed   Mentions: 71     Fields:    Translation:HumansAnimalsCells
  39. Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma. J Nucl Med. 2023 01; 64(1):137-144. Shin J, Parker MFL, Zhu I, Alanizi A, Rodriguez CI, Liu R, Watchmaker PB, Kalita M, Blecha J, Luu J, Wright B, Lapi SE, Flavell RR, Okada H, Tlsty TD, Roybal KT, Wilson DM. PMID: 35981900; PMCID: PMC9841254.
    View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
  40. Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma. Curr Opin Oncol. 2022 11 01; 34(6):661-669. Watchmaker PB, Colton M, Pineo-Cavanaugh PL, Okada H. PMID: 35855503; PMCID: PMC9560977.
    View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
  41. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2022 Jun 15; 132(12). Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, Gilbert RD, Nazarian J, Molinaro AM, Butterfield LH, Prados MD, Okada H. PMID: 35703183; PMCID: PMC9203080.
    View in: PubMed   Mentions: 3     Fields:    
  42. The future of cancer immunotherapy for brain tumors: a collaborative workshop. J Transl Med. 2022 05 23; 20(1):236. Brown CE, Bucktrout S, Butterfield LH, Futer O, Galanis E, Hormigo A, Lim M, Okada H, Prins R, Marr SS, Tanner K. PMID: 35606815; PMCID: PMC9125824.
    View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
  43. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. J Immunother Cancer. 2022 05; 10(5). Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, Tron AE, Hyer ML, Montoya M, Mende AL, Nejo T, Downey KM, Diebold D, Lu M, Nicolay B, Okada H. PMID: 35606087; PMCID: PMC9174833.
    View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
  44. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. Neuro Oncol. 2022 02 01; 24(2):259-272. Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H. PMID: 34347086; PMCID: PMC8804899.
    View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
  45. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022 02 01; 132(3). Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. PMID: 34882581; PMCID: PMC8803342.
    View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsPHPublic Health
  46. The immunology of low-grade gliomas. Neurosurg Focus. 2022 02; 52(2):E2. Haddad AF, Young JS, Oh JY, Okada H, Aghi MK. PMID: 35104791; PMCID: PMC9283531.
    View in: PubMed   Mentions: 22     Fields:    Translation:Humans
  47. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022 01; 3(1):11-24. Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF. PMID: 35121998.
    View in: PubMed   Mentions: 25     Fields:    Translation:Humans
  48. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J Immunother Cancer. 2021 06; 9(6). Simonds EF, Lu ED, Badillo O, Karimi S, Liu EV, Tamaki W, Rancan C, Downey KM, Stultz J, Sinha M, McHenry LK, Nasholm NM, Chuntova P, Sundström A, Genoud V, Shahani SA, Wang LD, Brown CE, Walker PR, Swartling FJ, Fong L, Okada H, Weiss WA, Hellström M. PMID: 34083417; PMCID: PMC8183210.
    View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
  49. IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity. J Immunother Cancer. 2021 06; 9(6). Ohkuri T, Kosaka A, Ikeura M, Salazar AM, Okada H. PMID: 34193567; PMCID: PMC8246372.
    View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
  50. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021 04 28; 13(591). Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, Cho J, Briones JD, Duecker JM, Goretsky YE, Dannenfelser R, Cardarelli L, Troyanskaya O, Sidhu SS, Roybal KT, Okada H, Lim WA. PMID: 33910979; PMCID: PMC8362330.
    View in: PubMed   Mentions: 204     Fields:    Translation:AnimalsCells
  51. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375. Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown CE, Chen Y, Fecci PE, Reardon DA, Dunn GP, Liau LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins RM, Platten M, Okada H. PMID: 33367885; PMCID: PMC7992879.
    View in: PubMed   Mentions: 62     Fields:    Translation:Humans
  52. The evolution of alternative splicing in glioblastoma under therapy. Genome Biol. 2021 01 26; 22(1):48. Wang L, Shamardani K, Babikir H, Catalan F, Nejo T, Chang S, Phillips JJ, Okada H, Diaz AA. PMID: 33499924; PMCID: PMC7835670.
    View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
  53. Current Advances in Immunotherapy for Glioblastoma. Curr Oncol Rep. 2021 01 26; 23(2):21. Mende AL, Schulte JD, Okada H, Clarke JL. PMID: 33496872; PMCID: PMC7838142.
    View in: PubMed   Mentions: 23     Fields:    Translation:Humans
  54. Assessing Oximetry Response to Chimeric Antigen Receptor T-cell Therapy against Glioma with 19F MRI in a Murine Model. Radiol Imaging Cancer. 2021 01; 3(1):e200062. Chapelin F, Leach BI, Chen R, Lister D, Messer K, Okada H, Ahrens ET. PMID: 33575659; PMCID: PMC7850236.
    View in: PubMed   Mentions: 8     Fields:    Translation:Animals
  55. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI Insight. 2021 01 11; 6(1). Nair S, Mazzoccoli L, Jash A, Govero J, Bais SS, Hu T, Fontes-Garfias CR, Shan C, Okada H, Shresta S, Rich JN, Shi PY, Diamond MS, Chheda MG. PMID: 33232299; PMCID: PMC7821591.
    View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
  56. Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Rev Neurother. 2021 02; 21(2):205-219. Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H. PMID: 33225764; PMCID: PMC7880880.
    View in: PubMed   Mentions: 7     Fields:    Translation:Humans
  57. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2020 12 01; 130(12):6325-6337. Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, Gilbert RD, Nazarian J, Molinaro AM, Butterfield LH, Prados MD, Okada H. PMID: 32817593; PMCID: PMC7685729.
    View in: PubMed   Mentions: 66     Fields:    Translation:HumansCellsCTClinical Trials
  58. The current state of immunotherapy for primary and secondary brain tumors: similarities and differences. Jpn J Clin Oncol. 2020 Oct 22; 50(11):1231-1245. Nejo T, Mende A, Okada H. PMID: 32984905; PMCID: PMC7733526.
    View in: PubMed   Mentions: 4     Fields:    Translation:Humans
  59. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. J Immunother Cancer. 2020 08; 8(2). Ascierto PA, Bifulco C, Galon J, Garbe C, Khleif SN, McQuade J, Odunsi K, Okada H, Paulos CM, Quezada SA, Tawbi HA, Timmerman J, Trinchieri G, Butterfield LH, Puzanov I. PMID: 32843491; PMCID: PMC7449295.
    View in: PubMed   Mentions: 1     Fields:    Translation:Humans
  60. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. J Neurooncol. 2020 Apr; 147(2):281-295. Kwok D, Okada H. PMID: 32185647; PMCID: PMC7182069.
    View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
  61. Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Neurooncol Pract. 2020 Oct; 7(5):465-476. Montoya ML, Kasahara N, Okada H. PMID: 33014387; PMCID: PMC7516091.
    View in: PubMed   Mentions: 14  
  62. Tumor antigens in glioma. Semin Immunol. 2020 02; 47:101385. Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H. PMID: 32037183.
    View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
  63. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun. 2020 Jan 27; 11(1):524. Mosaheb MM, Dobrikova EY, Brown MC, Yang Y, Cable J, Okada H, Nair SK, Bigner DD, Ashley DM, Gromeier M. PMID: 31988324; PMCID: PMC6985231.
    View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
  64. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). J Immunother Cancer. 2019 11 29; 7(1):332. Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I. PMID: 31783779; PMCID: PMC6884742.
    View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
  65. Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. J Neurooncol. 2020 Jan; 146(1):71-78. Alcaide-Leon P, Luks TL, Lafontaine M, Lupo JM, Okada H, Clarke JL, Villanueva-Meyer JE. PMID: 31728884; PMCID: PMC6939141.
    View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
  66. Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection. Magn Reson Med. 2020 03; 83(3):974-987. Hingorani DV, Chapelin F, Stares E, Adams SR, Okada H, Ahrens ET. PMID: 31631402; PMCID: PMC6879799.
    View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
  67. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol Cell Proteomics. 2019 06; 18(6):1255-1268. Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. PMID: 31154438; PMCID: PMC6553928.
    View in: PubMed   Mentions: 28     Fields:    Translation:Humans
  68. Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. Mol Cell Proteomics. 2019 Jun; 18(6):1270. Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. PMID: 31154440; PMCID: PMC6553924.
    View in: PubMed   Mentions:    Fields:    
  69. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. J Immunother Cancer. 2019 02 27; 7(1):58. Pinton L, Masetto E, Vettore M, Solito S, Magri S, D'Andolfi M, Del Bianco P, Lollo G, Benoit JP, Okada H, Diaz A, Della Puppa A, Mandruzzato S. PMID: 30813960; PMCID: PMC6391795.
    View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
  70. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019 02; 566(7745):E13. Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. PMID: 30733620.
    View in: PubMed   Mentions: 5     Fields:    
  71. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. Front Immunol. 2018; 9:3062. Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H. PMID: 30740109; PMCID: PMC6357938.
    View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
  72. Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurg. 2019 Apr; 124:397-409. Young JS, Dayani F, Morshed RA, Okada H, Aghi MK. PMID: 30677574; PMCID: PMC6642850.
    View in: PubMed   Mentions: 15     Fields:    
  73. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019 01; 565(7738):240-245. Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. PMID: 30568303.
    View in: PubMed   Mentions: 459     Fields:    Translation:HumansCellsCTClinical Trials
  74. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology. 2018; 7(12):e1501137. Genoud V, Marinari E, Nikolaev SI, Castle JC, Bukur V, Dietrich PY, Okada H, Walker PR. PMID: 30524896; PMCID: PMC6279422.
    View in: PubMed   Mentions: 83     Fields:    
  75. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol Cell Proteomics. 2018 11; 17(11):2132-2145. Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A. PMID: 30072578; PMCID: PMC6210219.
    View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
  76. Immunotherapy of Primary Brain Tumors: Facts and Hopes. Clin Cancer Res. 2018 11 01; 24(21):5198-5205. Buerki RA, Chheda ZS, Okada H. PMID: 29871908; PMCID: PMC6214775.
    View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
  77. Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. JCI Insight. 2018 04 05; 3(7). Müller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF, Kohanbash G. PMID: 29618666; PMCID: PMC5928860.
    View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
  78. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017 Dec 20; 18(1):234. Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E, Malatesta M, Amankulor NM, Kriegstein AR, Lim DA, Aghi M, Okada H, Diaz A. PMID: 29262845; PMCID: PMC5738907.
    View in: PubMed   Mentions: 355     Fields:    Translation:HumansAnimalsCells
  79. Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model. Sci Rep. 2017 12 18; 7(1):17748. Chapelin F, Gao S, Okada H, Weber TG, Messer K, Ahrens ET. PMID: 29255242; PMCID: PMC5735180.
    View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
  80. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 2018 01 02; 215(1):141-157. Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H. PMID: 29203539; PMCID: PMC5748856.
    View in: PubMed   Mentions: 137     Fields:    Translation:HumansAnimalsCells
  81. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. Oncoimmunology. 2018; 7(2):e1391972. Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY. PMID: 29308320; PMCID: PMC5749651.
    View in: PubMed   Mentions: 25     Fields:    
  82. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 07 19; 9(399). O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. PMID: 28724573; PMCID: PMC5762203.
    View in: PubMed   Mentions: 921     Fields:    Translation:HumansCTClinical Trials
  83. Is the immune response a friend or foe for viral therapy of glioma? Neuro Oncol. 2017 07 01; 19(7):882-883. Okada H, Thorne SH. PMID: 28874006; PMCID: PMC5737571.
    View in: PubMed   Mentions: 2     Fields:    Translation:Humans
  84. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017 Apr 03; 127(4):1425-1437. Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H. PMID: 28319047; PMCID: PMC5373859.
    View in: PubMed   Mentions: 245     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  85. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene. 2017 06 29; 36(26):3749-3759. Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK. PMID: 28218903; PMCID: PMC5491354.
    View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimalsCells
  86. Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience. Neuroimaging Clin N Am. 2017 Feb; 27(1):155-166. Furtado AD, Ceschin R, Blüml S, Mason G, Jakacki RI, Okada H, Pollack IF, Panigrahy A. PMID: 27889021; PMCID: PMC5127439.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  87. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016 12; 130(3):543-552. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. PMID: 27624915; PMCID: PMC5560602.
    View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
  88. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol. 2016 12; 130(3):517-527. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. PMID: 27624914; PMCID: PMC5363717.
    View in: PubMed   Mentions: 30     Fields:    Translation:Humans
  89. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep. 2016 08 10; 6:31397. Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM. PMID: 27507680; PMCID: PMC4979036.
    View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
  90. Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther. 2016 10; 16(10):1265-75. Lin Y, Okada H. PMID: 27434205; PMCID: PMC5133460.
    View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
  91. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 2016 10; 18(10):1402-12. Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N. PMID: 27116977; PMCID: PMC5035522.
    View in: PubMed   Mentions: 93     Fields:    Translation:HumansCells
  92. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016 08; 18(8):1157-68. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. PMID: 26984745; PMCID: PMC4933485.
    View in: PubMed   Mentions: 47     Fields:    Translation:HumansPHPublic Health
  93. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. PMID: 27471611; PMCID: PMC4938323.
    View in: PubMed   Mentions: 11     Fields:    
  94. The role of emerging therapy in the management of patients with diffuse low grade glioma. J Neurooncol. 2015 Dec; 125(3):631-5. Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. PMID: 26530260.
    View in: PubMed   Mentions: 4     Fields:    Translation:Humans
  95. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. PMID: 26545842; PMCID: PMC4638131.
    View in: PubMed   Mentions: 372     Fields:    Translation:Humans
  96. Principles of immunology and its nuances in the central nervous system. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii3-vii8. Dunn GP, Okada H. PMID: 26516224; PMCID: PMC4625893.
    View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
  97. Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. Oncoimmunology. 2015 Nov; 4(11):e1047581. Ahn B, Kohanbash G, Ohkuri T, Kosaka A, Chen X, Ikeura M, Wang TC, Okada H. PMID: 26451324; PMCID: PMC4589044.
    View in: PubMed   Mentions: 9     Fields:    
  98. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology. 2015 Jun; 4(6):e1008347. Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL. PMID: 26155415; PMCID: PMC4485717.
    View in: PubMed   Mentions: 68     Fields:    
  99. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015 Jul; 123(3):339-46. Reardon DA, Okada H. PMID: 25707876.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  100. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18; 7(275):275ra22. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV. PMID: 25696001; PMCID: PMC4467166.
    View in: PubMed   Mentions: 255     Fields:    Translation:HumansAnimals
  101. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochem Biophys Res Commun. 2015 Mar 13; 458(3):549-554. Kosaka A, Ohkuri T, Ikeura M, Kohanbash G, Okada H. PMID: 25677619; PMCID: PMC4355048.
    View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
  102. Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. Oncoimmunology. 2015 Apr; 4(4):e999523. Ohkuri T, Ghosh A, Kosaka A, Sarkar SN, Okada H. PMID: 26137417; PMCID: PMC4485761.
    View in: PubMed   Mentions: 14     Fields:    
  103. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30; 5(24):12472-508. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fucíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. PMID: 25537519; PMCID: PMC4350348.
    View in: PubMed   Mentions: 206     Fields:    Translation:HumansAnimals
  104. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer. 2014; 2(1):46. Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR. PMID: 25598973; PMCID: PMC4296547.
    View in: PubMed   Mentions: 42     Fields:    
  105. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015 Jan 15; 21(2):286-94. Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS. PMID: 25424847; PMCID: PMC4297523.
    View in: PubMed   Mentions: 60     Fields:    Translation:HumansCellsCTClinical Trials
  106. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014 Dec; 2(12):1199-208. Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, Watkins SC, Sarkar SN, Okada H. PMID: 25300859; PMCID: PMC4258479.
    View in: PubMed   Mentions: 131     Fields:    Translation:AnimalsCells
  107. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 01; 32(19):2050-8. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H. PMID: 24888813; PMCID: PMC4067943.
    View in: PubMed   Mentions: 109     Fields:    Translation:HumansCTClinical Trials
  108. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother. 2014 Aug; 63(8):847-57. Kosaka A, Ohkuri T, Okada H. PMID: 24878890; PMCID: PMC4221287.
    View in: PubMed   Mentions: 68     Fields:    Translation:AnimalsCells
  109. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer. 2013; 1:21. Ohno M, Ohkuri T, Kosaka A, Tanahashi K, June CH, Natsume A, Okada H. PMID: 24829757; PMCID: PMC4019893.
    View in: PubMed   Mentions: 55     Fields:    
  110. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel). 2013 Nov 01; 5(4):1379-412. Ahn BJ, Pollack IF, Okada H. PMID: 24202450; PMCID: PMC3875944.
    View in: PubMed   Mentions: 23  
  111. Ependymomas: development of immunotherapeutic strategies. Expert Rev Neurother. 2013 Oct; 13(10):1089-98. Pollack IF, Jakacki RI, Butterfield LH, Okada H. PMID: 24117271; PMCID: PMC3972122.
    View in: PubMed   Mentions: 6     Fields:    Translation:Humans
  112. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res. 2013 Nov 01; 73(21):6413-23. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H. PMID: 24030977; PMCID: PMC3829000.
    View in: PubMed   Mentions: 108     Fields:    Translation:HumansAnimalsCells
  113. Peptide vaccine therapy for childhood gliomas. Neurosurgery. 2013 Aug; 60 Suppl 1:113-9. Pollack IF, Jakacki RI, Butterfield LH, Okada H. PMID: 23839362.
    View in: PubMed   Mentions: 7     Fields:    Translation:Humans
  114. In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imaging. PLoS One. 2013; 8(5):e59479. Zhong J, Sakaki M, Okada H, Ahrens ET. PMID: 23667419; PMCID: PMC3648573.
    View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
  115. Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci. 2013 May; 1284:17-23. Okada H, Scheurer ME, Sarkar SN, Bondy ML. PMID: 23651189; PMCID: PMC3648859.
    View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
  116. Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol. 2013 Jul; 15(7):891-903. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H. PMID: 23595625; PMCID: PMC3688013.
    View in: PubMed   Mentions: 47     Fields:    Translation:AnimalsCells
  117. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res. 2013 Apr 01; 19(7):1816-26. Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. PMID: 23401227; PMCID: PMC3618546.
    View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
  118. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. J Neurooncol. 2013 Jan; 111(2):103-11. Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. PMID: 23179498; PMCID: PMC3546121.
    View in: PubMed   Mentions: 19     Fields:    Translation:Humans
  119. Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Adv Virol. 2012; 2012:815465. Reinhart B, Mazzacurati L, Forero A, Hong CS, Eguchi J, Okada H, Fellows W, Niranjan A, Cohen JB, Glorioso JC, Grandi P. PMID: 22924042; PMCID: PMC3424635.
    View in: PubMed   Mentions: 6  
  120. Differential activity of interferon-α8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma. Oncoimmunology. 2012 Jul 01; 1(4):487-492. Kohanbash G, Ishikawa E, Fujita M, Ikeura M, McKaveney K, Zhu J, Sakaki M, Sarkar SN, Okada H. PMID: 22754767; PMCID: PMC3382910.
    View in: PubMed   Mentions: 7     Fields:    
  121. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108. Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I. PMID: 22640522; PMCID: PMC3404934.
    View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
  122. Type17 T-cells in central nervous system autoimmunity and tumors. J Clin Immunol. 2012 Aug; 32(4):802-8. Okada H, Khoury SJ. PMID: 22454247; PMCID: PMC3389562.
    View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
  123. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy. 2012 Jul; 14(6):733-42. Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, Yoshida J, Suzuki S, Nishikawa H, Shiku H, Natsume A, Wakabayashi T. PMID: 22424217.
    View in: PubMed   Mentions: 41     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  124. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol. 2012 Feb 15; 188(4):1782-8. Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ. PMID: 22246626; PMCID: PMC3273624.
    View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
  125. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol Invest. 2012; 41(6-7):658-79. Kohanbash G, Okada H. PMID: 23017140.
    View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
  126. MicroRNAs and STAT interplay. Semin Cancer Biol. 2012 Feb; 22(1):70-5. Kohanbash G, Okada H. PMID: 22210182; PMCID: PMC3288787.
    View in: PubMed   Mentions: 51     Fields:    Translation:Humans
  127. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2012 Jun; 61(6):789-801. Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H. PMID: 22065046; PMCID: PMC3365630.
    View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
  128. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res. 2011 Aug; 50(2-3):235-47. Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. PMID: 21717071; PMCID: PMC3695396.
    View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
  129. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest. 2011 Jul; 121(7):2554-69. Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY. PMID: 21670504; PMCID: PMC3223821.
    View in: PubMed   Mentions: 40     Fields:    Translation:AnimalsCells
  130. Do we need novel radiologic response criteria for brain tumor immunotherapy? Expert Rev Neurother. 2011 May; 11(5):619-22. Okada H, Pollack IF. PMID: 21539483.
    View in: PubMed   Mentions: 17     Fields:    Translation:Humans
  131. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011 Apr 01; 71(7):2664-74. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H. PMID: 21324923; PMCID: PMC3075086.
    View in: PubMed   Mentions: 223     Fields:    Translation:AnimalsCells
  132. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011 Jan 20; 29(3):330-6. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. PMID: 21149657; PMCID: PMC3056467.
    View in: PubMed   Mentions: 309     Fields:    Translation:HumansCellsCTClinical Trials
  133. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol. 2011 Aug; 104(1):83-92. Zhu X, Fujita M, Snyder LA, Okada H. PMID: 21116835; PMCID: PMC3068234.
    View in: PubMed   Mentions: 117     Fields:    
  134. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother. 2010 Sep; 59(9):1401-9. Zhu X, Fallert-Junecko BA, Fujita M, Ueda R, Kohanbash G, Kastenhuber ER, McDonald HA, Liu Y, Kalinski P, Reinhart TA, Salazar AM, Okada H. PMID: 20549206; PMCID: PMC2893267.
    View in: PubMed   Mentions: 56     Fields:    
  135. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res. 2010 Jul 01; 16(13):3409-19. Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, Kato H, Bondy ML, Ohlfest JR, Okada H. PMID: 20472682; PMCID: PMC2896455.
    View in: PubMed   Mentions: 56     Fields:    
  136. A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS One. 2010 May 05; 5(5):e10492. Steitz J, Barlow PG, Hossain J, Kim E, Okada K, Kenniston T, Rea S, Donis RO, Gambotto A. PMID: 20463955; PMCID: PMC2864737.
    View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  137. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol. 2010 Jun; 22(3):173-82. Kalinski P, Okada H. PMID: 20409732; PMCID: PMC2892234.
    View in: PubMed   Mentions: 34     Fields:    
  138. miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med. 2010 Feb 18; 8:17. Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, Wang E, Fujita M, Okada H. PMID: 20167088; PMCID: PMC2836279.
    View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
  139. MicroRNAs in immune regulation--opportunities for cancer immunotherapy. Int J Biochem Cell Biol. 2010 Aug; 42(8):1256-61. Okada H, Kohanbash G, Lotze MT. PMID: 20144731; PMCID: PMC2889234.
    View in: PubMed   Mentions: 39     Fields:    
  140. Balb/c EGFP mice are tolerant against immunization utilizing recombinant adenoviral-based vectors encoding EGFP: a novel model for the study of tolerance mechanisms and vaccine efficacy. Mol Immunol. 2010 Feb; 47(5):1149-53. Steitz J, Soloff AC, Barratt-Boyes SM, Alber SM, Watkins SC, Okada H, Gambotto A. PMID: 20022379.
    View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
  141. Immunotherapy for pediatric central nervous system tumors. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S75-81. Gardner SL, Ahmed N, Okada H. PMID: 19896544.
    View in: PubMed   Mentions:    Fields:    Translation:HumansCells
  142. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res. 2009 Nov 01; 15(21):6551-9. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H. PMID: 19861464; PMCID: PMC2783346.
    View in: PubMed   Mentions: 62     Fields:    
  143. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother. 2009 Oct; 32(8):793-802. Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ. PMID: 19752754; PMCID: PMC2796294.
    View in: PubMed   Mentions: 17     Fields:    
  144. Brain tumor immunotherapy with type-1 polarizing strategies. Ann N Y Acad Sci. 2009 Sep; 1174:18-23. Okada H. PMID: 19769732.
    View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
  145. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A. 2009 Jun 30; 106(26):10746-51. Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, Khan SA, Sobol RW, Okada H. PMID: 19520829; PMCID: PMC2705554.
    View in: PubMed   Mentions: 96     Fields:    Translation:HumansCells
  146. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther. 2009 Dec; 16(12):883-91. Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ. PMID: 19444303; PMCID: PMC3427922.
    View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
  147. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. Cancer Res. 2009 Feb 15; 69(4):1587-95. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H. PMID: 19190335; PMCID: PMC5450639.
    View in: PubMed   Mentions: 54     Fields:    
  148. Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009; 29(1):1-42. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M. PMID: 19348609; PMCID: PMC2713019.
    View in: PubMed   Mentions: 63     Fields:    
  149. IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur J Immunol. 2008 Oct; 38(10):2865-73. Sasaki K, Pardee AD, Okada H, Storkus WJ. PMID: 18958887; PMCID: PMC2771926.
    View in: PubMed   Mentions: 8     Fields:    
  150. Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol. 2008 Jul 01; 181(1):104-8. Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ. PMID: 18566374; PMCID: PMC2596982.
    View in: PubMed   Mentions: 15     Fields:    
  151. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol. 2008 Jul; 88(3):245-50. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF. PMID: 18324354; PMCID: PMC2561297.
    View in: PubMed   Mentions: 47     Fields:    
  152. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol. 2008 Feb 15; 180(4):2089-98. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, Okada H. PMID: 18250414.
    View in: PubMed   Mentions: 44     Fields:    Translation:AnimalsCells
  153. Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med. 2007 Dec 19; 5:68. Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, Whiteside TL, Butterfield LH, Okada H. PMID: 18093336; PMCID: PMC2244605.
    View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
  154. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007 Dec 19; 5:67. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC, Pollack IF. PMID: 18093335; PMCID: PMC2254376.
    View in: PubMed   Mentions: 63     Fields:    Translation:HumansCellsCTClinical Trials
  155. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res. 2007 Oct 15; 67(20):10012-8. Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P. PMID: 17942935; PMCID: PMC2905256.
    View in: PubMed   Mentions: 14     Fields:    
  156. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 2007 Jul 01; 67(13):6451-8. Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H. PMID: 17616706.
    View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
  157. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. J Immunol. 2007 Mar 15; 178(6):3400-8. Berhanu A, Huang J, Watkins SC, Okada H, Storkus WJ. PMID: 17339434.
    View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
  158. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007 Feb 12; 5:10. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H. PMID: 17295916; PMCID: PMC1802742.
    View in: PubMed   Mentions: 87     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  159. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):566-575. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR. PMID: 17255279; PMCID: PMC4030524.
    View in: PubMed   Mentions: 79     Fields:    Translation:HumansCells
  160. Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol. 2007; 377:203-22. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J. PMID: 17634619.
    View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
  161. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 2006 Jun 01; 66(11):5883-91. Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H. PMID: 16740728.
    View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
  162. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 2006 Apr 15; 66(8):4478-87. Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H. PMID: 16618775.
    View in: PubMed   Mentions: 40     Fields:    Translation:AnimalsCells
  163. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther. 2005 Sep; 12(9):757-68. Sato H, Kuwashima N, Sakaida T, Hatano M, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Okada H. PMID: 15832173.
    View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
  164. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol. 2005 Aug 15; 175(4):2730-40. Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T, Sakaida T, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Storkus WJ, Okada H. PMID: 16081851.
    View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
  165. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005 Aug; 7(8):717-22. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H. PMID: 16207473; PMCID: PMC1501889.
    View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
  166. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol. 2005 Jun 01; 174(11):7194-201. Eguchi J, Kuwashima N, Hatano M, Nishimura F, Dusak JE, Storkus WJ, Okada H. PMID: 15905564.
    View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
  167. [Immunotherapy for brain tumor: don't get "Lost in Translation"]. No Shinkei Geka. 2005 May; 33(5):433-42. Okada H. PMID: 15912763.
    View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
  168. The characterization of tumor apoptosis after experimental radiosurgery. Stereotact Funct Neurosurg. 2005; 83(1):17-24. Witham TF, Okada H, Fellows W, Hamilton RL, Flickinger JC, Chambers WH, Pollack IF, Watkins SC, Kondziolka D. PMID: 15775705.
    View in: PubMed   Mentions: 12     Fields:    Translation:Animals
  169. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004 Nov 24; 2(1):40. Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. PMID: 15563374; PMCID: PMC535538.
    View in: PubMed   Mentions: 31     Fields:    
  170. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther. 2004 Nov; 11(21):1551-8. Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H. PMID: 15343358.
    View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
  171. Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther. 2004 Oct; 4(10):1609-20. Okada H, Pollack IF. PMID: 15461572.
    View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  172. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res. 2004 Aug 15; 64(16):5830-8. Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF. PMID: 15313927.
    View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
  173. Biologic therapy for brain cancers--based on cellular and immunobiology. Yonsei Med J. 2004 Jun 30; 45 Suppl:68-70. Okada H. PMID: 15250054.
    View in: PubMed   Mentions:    Fields:    Translation:Humans
  174. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003 Oct 01; 63(19):6378-86. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ. PMID: 14559827.
    View in: PubMed   Mentions: 41     Fields:    Translation:AnimalsCells
  175. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol. 2003 Aug-Sep; 64(1-2):13-20. Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MJ, Cai Q, Elder EH, Whiteside TL, Schold SC, Pollack IF. PMID: 12952282.
    View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
  176. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol. 2003 Aug-Sep; 64(1-2):63-9. Witham TF, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, Chambers WH. PMID: 12952287.
    View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
  177. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther. 2003 Jul; 10(7):549-58. Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H. PMID: 12833135.
    View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
  178. Gene therapy and biologic therapy with interleukin-4. Curr Gene Ther. 2002 Dec; 2(4):437-50. Okada H, Kuwashima N. PMID: 12477255.
    View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
  179. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002 Sep; 8(9):2851-5. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. PMID: 12231526.
    View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
  180. 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery. 2002 Jun; 50(6):1327-34; discussion 1334-5. Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF. PMID: 12015852.
    View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCellsPHPublic Health
  181. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 2002 May 01; 62(9):2583-91. Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, Kondziolka D, Okada H, Pollack IF, Chambers WH. PMID: 11980653.
    View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
  182. Combination of stereotactic radiosurgery and cytokine gene-transduced tumor cell vaccination: a new strategy against metastatic brain tumors. J Neurosurg. 2001 Dec; 95(6):984-9. Nakahara N, Okada H, Witham TF, Attanucci J, Fellows WK, Chambers WH, Niranjan A, Kondziolka D, Pollack IF. PMID: 11765844.
    View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
  183. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther. 2001 Aug; 8(15):1157-66. Okada H, Villa L, Attanucci J, Erff M, Fellows WK, Lotze MT, Pollack IF, Chambers WH. PMID: 11509946.
    View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
  184. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther. 2001 Mar 20; 12(5):575-95. Okada H, Pollack IF, Lieberman F, Lunsford LD, Kondziolka D, Schiff D, Attanucci J, Edington H, Chambers W, Kalinski P, Kinzler D, Whiteside T, Elder E, Potter D. PMID: 11268289.
    View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  185. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res. 2001 Mar 15; 61(6):2625-31. Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack LF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH. PMID: 11289140.
    View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
  186. Exploitation of immune mechanisms in the treatment of central nervous system cancer. Semin Pediatr Neurol. 2000 Jun; 7(2):131-43. Pollack IF, Okada H, Chambers WH. PMID: 10914414.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
  187. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res. 2000 May 01; 60(9):2449-57. Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH. PMID: 10811123.
    View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
  188. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther. 2000 Mar; 7(3):486-94. Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT. PMID: 10766355.
    View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
  189. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther. 2000 Mar 01; 11(4):637-53. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, Schiff D, Attanucci J, Edington H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E. PMID: 10724042.
    View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
  190. Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S61-6. Lotze MT, Shurin M, Esche C, Tahara H, Storkus W, Kirkwood JM, Whiteside TL, Elder EM, Okada H, Robbins P. PMID: 10685662.
    View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
  191. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 1999 Feb; 6(2):219-26. Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME. PMID: 10435106.
    View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
  192. [Neurosurgery and molecular biology: (series 10) gene therapy and biological therapy for brain tumors]. No Shinkei Geka. 1999 Jan; 27(1):9-17. Okada H. PMID: 10024979.
    View in: PubMed   Mentions:    Fields:    Translation:HumansCells
  193. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer. 1998 Oct 05; 78(2):196-201. Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME. PMID: 9754652.
    View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
Hideho's Networks
Concepts (535)
Derived automatically from this person's publications.
Explore
_
Co-Authors (109)
People in Profiles who have published with this person.
Explore
_
Similar People (60)
People who share similar concepts with this person.
Explore
_
Same Department
Search Department
_

UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-12-gbedcc43d on PROFILES-PWEB04.

Copyright ©2025 The Regents of the University of California.